ZE63-0302 not checked

Eilean Therapeutics

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Type 2 Diabetes
Main trialPhase 1
“A first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of ZE63-0302 administered orally in healthy volunteers.”In the company’s words, NCT06780124 on ClinicalTrials.gov

Other drugs for Type 2 Diabetes

All 128 drugs for Type 2 Diabetes

Coming up0

No dates coming up.

Changes1

Last 90 days

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Completed 24 Jun 2025 Сlinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of ZE63-0302 in Healthy Volunteers
Phase 1Completed 21 Apr 2026 Study to Assess Safety, Tolerability, PK, and PD of Multiple Doses of ZE63-0302 Administrated Orally in T2DM Patients.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ZE63-0302

Following is part of Solo: you see every change to ZE63-0302 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in